Synageva BioPharma Presents Sebelipase Alfa Data At The Meeting

After completing the initial four-week portion of the trial, patients were allowed to continue treatment with sebelipase alfa as part of a long-term, open-label extension study. Eight of nine patients enrolled in the extension study and continue treatment with sebelipase alfa.

http://ift.tt/1sXTd85